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Abstract
Background: Granulin-epithelin precursor (GEP) is a secretory growth factor, which has been demonstrated to
control cancer growth, invasion, drug resistance and immune escape. Our previous studies and others also
demonstrated its potential in targeted therapy. Comprehensive characterization of GEP partner on cancer cells are
warranted. We have previously shown that GEP interacted with heparan sulfate on the surface of liver cancer cells
and the interaction is crucial for GEP-mediated signaling transduction. This study aims to characterize GEP protein
partner at the cell membrane with the co-immunoprecipitation and mass spectrometry approach.
Methods: The membrane fraction from liver cancer model Hep3B was used for capturing binding partner with the
specific monoclonal antibody against GEP. The precipitated proteins were analyzed by mass spectrometry. After
identifying the GEP binding partner, this specific interaction was validated in additional liver cancer cell line HepG2
by co-immunoprecipitation using GRP78 and GEP antibodies, respectively, as the bait. GRP78 transcript levels in
hepatocellular carcinoma (HCC) clinical samples (n = 77 pairs) were examined by real-time quantitative RT-PCR. GEP
and GRP78 protein expressions were investigated by immunohistochemistry on paraffin sections.
Results: We identified the GEP-binding protein as 78-kDa glucose-regulated protein (GRP78, also named heat shock
70-kDa protein 5, HSPA5). This interaction was validated in independent HCC cell lines. Increased GRP78 mRNA
levels were demonstrated in liver cancer tissues compared with the paralleled liver tissues (t-test, P = 0.002). GRP78
and GEP transcript levels were significantly correlated (Spearman’s correlation, P = 0.001), and the proteins were
also detectable in the cytoplasm of liver cancer cells by immunohistochemical staining.
Conclusions: GRP78 and GEP are interacting protein partners in liver cancer cells and may play a role in GEP-mediated
cancer progression in HCC.
Keywords: Granulin-epithelin precursor, 78-kDa glucose-regulated protein, Hepatocellular carcinoma, Mass
spectrometry, Protein interaction
Background
The secretory growth factor granulin-epithelin precursor
(GEP) is also known as progranulin or PC cell-derived
growth factor. It constitutes of seven and half cysteine rich
granulin subunits, which are known to regulate inflamma-
tion [1]. The precursor GEP protein plays different roles
in a range of physiological mechanisms including neur-
onal survival [2, 3], fetal development [4], wound response
[5] and cancer progression [6]. We previously showed that
GEP was over-expressed in over 70% of human hepatocel-
lular carcinoma (HCC) samples [7]. Functional studies
showed that GEP promoted cell proliferation, invasion,
chemo-resistance and immune escape in HCC [7–9].
HCC is the major form of primary liver cancers [10].
With about 745,500 deaths annually, it is the second
leading cause of cancer-related death globally in 2012
[11]. Dismal prognosis have been revealed in HCC
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patients with less than 20% survival rates in five years
[11]. This low survival rate reflects the fact that liver
cancer is frequently diagnosed at an advanced stage and
most patients at advanced stage of HCC could only re-
ceive systemic chemotherapies where the response rates
are less than 20% [12]. Limited patients are eligible for
curative therapeutic approaches which include percutan-
eous ablation, partial hepatectomy and transplantation
[13]. However, the 5-year recurrence rate is relatively
high with over 60% even after curative partial hepatec-
tomy [14]. Although HCC occurs most frequently in
Asia, incidence and mortality rates of HCC are increas-
ing rapidly in Western countries [15] such as the United
States [16]. Current technologies in HCC prognosis are
unsatisfactory, hence, a thorough understanding of the
mechanisms of HCC is essential for developing diagnos-
tic approaches and for seeking alternative or supportive
therapies to manage liver malignancy. GEP has been re-
cently shown as a potential therapeutic target for HCC by
using monoclonal antibody. Injection of GEP antibody
can suppress the growth of HCC tumor in mouse model
[17] and synergize with the anti-tumor effect of chemo-
therapeutic agents [18]. Therefore, a detailed understand-
ing of the mechanisms of GEP-mediated tumorigenesis in
HCC is urgently needed.
We have previously shown that heparan sulfate (HS)
might act as the co-receptor, which is essential in the cell
surface binding and the signaling transduction of GEP
[19]. Further investigation on the primary receptor of GEP
in human cancers is essential. In order to look for GEP
binding partners at cell membrane, this study employed
mass spectrometry to identify GEP binding proteins from
membrane fraction of HCC cells. The 78-kDa glucose-
regulated protein (GRP78), also referred as the heat shock
70 kDa protein 5 (HSPA5) and immunoglobulin binding
protein BiP, was identified to interact with GEP. This
interaction was validated by co-immunoprecipitation
using GRP78 antibody as bait. Clinical analysis showed
that expression of GRP78 was up-regulated in HCC tumor
and correlated with GEP expression.
Methods
Cell lines
Two human liver cancer cell lines, Hep3B and HepG2
(HB-8064 and HB-8065, respectively, American Type
Culture Collection, ATCC, Manassas, VA), were cultured in
advanced minimum essential medium (AMEM) supple-
mented with 10% fetal bovine serum and L-glutamine at
37 °C in a 5% CO2 incubator. GEP-overexpressed HepG2
(HepG2-FL) and Hep3B (Hep3B-FL) were generated by
lipofection of GEP plasmid as reported previously [7] and
were maintained in 0.4 and 0.2 mg/ml G418 respectively in
complete medium. Selection by drug was discontinued
during assays. Both cell lines were characterized by the
company.
Clinical samples
HCC patients were recruited between October 2002 and
September 2005 with written inform consent at Queen
Mary Hospital in Hong Kong. Real-time RT-PCR expres-
sion assays were performed with the snap frozen HCC
and the adjacent non-tumor (NT) tissue specimens. The
tissues were formalin-fixed and paraffin-embedded for
immunohistochemistry.
Recombinant GEP binding assay
Purification of recombinant GEP (rGEP) and the binding
assay were described previously [19]. Briefly, HCC cells
were detached by 5 mM EDTA and were incubated with
purified His-tagged rGEP. Flow cytometry was used to
measure the binding of rGEP by FITC-conjugated anti-
His antibody. For the determination of the non-HS bind-
ing, rGEP bound-cells were incubated with 10 μg/ml
heparin for 20 min at 4 °C with vortex. Cells with re-
sidual rGEP on the cell surface were incubated with
anti-His antibody for measurement of non-HS binding
by flow cytometry.
Membrane fraction enrichment
The GEP-overexpressing-Hep3B cells, Hep3B-FL, were
cultured for 3 days and were then washed with ice-cold
PBS buffer with 0.1% glucose and Tris-buffered sucrose
solution (250 mM sucrose, 0.1% glucose, 10 mM Tris,
pH 7.0). The cells were harvested by scraping and col-
lected by centrifugation for 5 min at 500×g at 4 °C. After
washing with Tris-buffered sucrose solution, cells were
resuspended and homogenized in solution A (20 mM
Tris, 5 mM MgCl2, 5 mM N-ethylmaleimide, 10 mM
EDTA, complete protease inhibitor cocktail, pH 7.2).
Cells debris was removed by centrifugation at 3000×g for
10 min. The supernatant containing the cellular protein
complexes and the homogenized membrane-anchored
protein complexes was collected. Supernatant was then
centrifuged at 20000×g for an hour to collect the pellet,
which contained the crude membrane fraction. The pellet
was lysed in lysis buffer (20 mM Tris, 5 mM MgCl2,
5 mM N-ethylmaleimide, 10 mM EDTA, complete prote-
ase inhibitor cocktail, 1% Triton X-100, 20% glycerol,
pH 7.2) under rotation at 4 °C for 1 h. Dissolved mem-
brane proteins were collected from the supernatant after
centrifugation at 20000×g for an hour. Membrane protein
concentration was analyzed by DC Protein Assay reagents
(BioRad, Philadelphia, PA).
Co-immunoprecipitation
Co-immunoprecipitation was performed as described
previously [20] with minor modifications. Briefly, cells
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were cultured in T175 flasks for 3 days under normal
conditions until the cells reached around 80% confluence.
The membrane fraction enriched protein lysate described
in the earlier section was incubated with monoclonal anti-
body anti-GEP antibody A23 (Versitech) [17] or anti-
GRP78 antibody (Cell Signaling), respectively, at a ratio of
400 μg to 2 μg. This mixture was incubated at 4 °C
overnight under rotation. Antibody alone and protein
lysate alone, respectively, were performed as inde-
pendent control reactions and served as references for
the non-specific bindings with Protein G Sepharose.
For each reaction, 100 μl of equilibrated protein G-
Sepharose beads (Amersham Biosciences, Piscataway, NJ)
were added to the antibody-lysate mixture and incubated
at 4 °C with rotation for an hour. The complexes were
briefly centrifuged after incubation. The supernatant was
discarded and the beads were washed with 500 μl lysis
buffer for 5 times to remove any unbound proteins. The
co-immunoprecipitated proteins were eluted by adding
SDS sample buffer to the protein G-Sepharose beads
followed by 5 min incubation at 95 °C.
SDS-PAGE and immunoblotting
Indicated amounts of proteins were separated in denatured
condition in SDS-PAGE gel. Proteins were stained by
Coomassie blue or electro-transferred onto polyvinylidene
fluoride membranes. For immunoblotting, the membrane
was blocked by 5% skim milk and subsequently incubated
overnight at 4 °C with corresponding primary antibodies.
Horseradish peroxidase-labeled secondary antibodies with
enhanced chemiluminescence (GE healthcare Life Sciences)
was used for detection.
Mass spectrometry
The differential protein band at about 85 kDa was ex-
cised from the Coomassie blue-stained gel, and in-gel
trypsin digestion was performed as previously described
[21]. Briefly, the gel was destained and reduced, followed
by alkylation and digestion. C18 ZipTips (Millipore
Corp., Billerica, MA) was used to desalt the tryptic
digested peptides. The desalted peptides were subjected to
MALDI-TOF/TOF MS (Ultraflex-III, Bruker Daltonics,
Bremen, Germany). The MS and MS/MS spectra were an-
alyzed with the FlexAnalysis program (version 3.0, Bruker
Daltonics) with default parameters. The matched peptides
of the MS spectrum were searched via the MASCOT
search engine for the protein identity using the peptide
mass fingerprinting (PMF) approach and the MS/MS ion
search approach. One missed cleavage in trypsin digestion
was allowed among the search parameters. Phosphoryl-
ation of serine/threonine/tyrosine, methionine partial
oxidation and iodoacetamide modification of cysteine resi-
dues were selected. The error tolerance values were
50 ppm and 0.1 Da, respectively, for the parent peptides
and MS/MS ion masses.
Real-time quantitative PCR
Real-time quantitative RT-PCR was performed as de-
scribed previously [7]. GRP78 primers and probe were
pre-made reagents (Pre-designed TaqMan Gene Expres-
sion Assay, Life Technologies). Reagents for control 18S
were Pre-designed TaqMan Assay Reagents (Life Tech-
nologies). The GRP78 mRNA expressions were exam-
ined in HCC and the corresponding non-tumor tissues
(n = 77 pairs). The GRP78 relative levels had been nor-
malized with control 18S and calibrator for RNA quantity
and plate-to-plate variation. The mRNA expression of
GEP has been determined previously in the same cohort
[19] and was used for correlation analysis in this study.
Immunohistochemistry
GEP and GRP78 proteins were examined by immunohis-
tochemistry [7, 17]. Monoclonal anti-GEP antibody
(Versitech) [17] at a dilution of 1:500 and polyclonal
anti-GRP78 antibody (Cell Signaling) at a dilution of
1:250 was used in the staining. Immunohistochemical
Fig. 1 Binding of rGEP on the surface of HCC cells includes a fraction of non-HS binding. After EDTA detachment, HCC cells (a) Hep3B and (b)
HepG2 were incubated with rGEP for cell surface binding. The HS-rGEP interaction was displaced by heparin. Residual binding (blue line) of rGEP
and control binding (red line) of rGEP were detected by anti-His antibody and quantified by flow cytometry. Grey area represents the background
fluorescent signal of cells without rGEP incubation. Representative histograms from three independent replicates are shown
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staining was performed with the Dako Envision Plus Sys-
tem (Dako, Carpinteria, CA). Briefly, sections were sub-
jected to deparaffinization and hydration, then 10 min
boiling in citrate buffer (pH 6) for antigen retrieval. Inacti-
vation of endogenous peroxidase, followed by primary
antibody incubation at room temperature, and signal de-
tection by horseradish peroxidase-conjugated secondary
antibody incubation at room temperature. Diaminobenzi-
dine served as the chromogen and visualized as brown
stain with hematoxylin counterstained.
Statistical analysis
Continuous variables were assessed by Spearman’s cor-
relation, comparison between groups by Student’s t-test
or one-way analysis of variance as appropriate and de-
scribed in the text. The Youden index (sensitivity + spe-
cificity - 1) was used to determine the optimal cutoff of
GRP78 expression for prediction of survival outcome.
Youden index was employed to maximize the sensitivity
(true-positive fraction) and specificity (1 - false-positive
fraction) of the prediction simultaneously. Descriptive
parameters were analyzed by chi-squared test with
Bonferroni correction. P values less than 0.05 were con-
sidered significant. Statistical analyses were performed
by SPSS (IBM SPSS Statistics for Windows, Version 21;
Armonk, NY).
Results
Non-HS binding sites on surface of HCC cells
The rGEP bound on the surface of HCC cells through
HS [19] could be displaced by adding heparin. However,
not all the rGEP was displaced and residual rGEP could
Table 1 Summary of the peptide masses and search results of the GEP predominant interacting partner GRP78 in the liver cancer
cell membrane fraction
Observed Da Mr(expt)a Mr(calc)b Ppmc Start-End Missd Ionse Peptide sequence
1528.6 1527.6 1527.7 −84.1 325–336 1 29 R.AKFEELNMDLFR.S + Oxidation(M)
1566.6 1565.6 1565.8 −85.4 61–74 0 19 R.ITPSYVAFTPEGER.L
1815.8 1814.8 1815.0 −84.8 198–214 1 55 R.IINEPTAAAIAYGLDKR.E
1833.7 1832.7 1832.9 −88.6 82–97 1 42 K.NQLTSNPENTVFDAKR.L
1887.8 1886.8 1887.0 −89.6 165–181 0 92 K.VTHAVVTVPAYFNDAQR.Q
aExperimental molecular mass (Dalton) of the peptide
bRelative molecular mass (Dalton) calculated from the matched peptide sequence
cparts per million, showing difference between the experimental and calculated masses
dnumber of missed cleavage sites
eions score
Fig. 2 Co-immunoprecipitation using GRP78 antibody and GEP
antibody respectively. Two sets of co-IP were performed using GRP78
antibody and GEP antibody, respectively, as baits. Each set of experiment
contains lysate with specific antibody (I), antibody alone (II) and lysate
alone (III). The proteins absorbed in the protein G beads were extracted
by boiling in SDS sampling buffer and were loaded in each lane.
Immunoblotting (IB) targeting GEP and GRP78 were performed.
Representative blots from three independent experiments are shown
Fig. 3 GRP78 and GEP protein expression in clinical samples by
immunohistochemical staining. HCC tissue and non-tumor (NT) liver
tissue from patients were formalin-fixed and paraffin-embedded.
Sections were deparaffinised and hydrated. Specific antibodies to (a)
GRP78 and (b) GEP were added and detected by HRP-conjugated
second antibody. The sections were counterstained with hematoxylin
and imaged at 400× magnification. Representative images from three
individual clinical sample pairs are shown
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be detected on the surface of HCC cells after heparin in-
cubation (Fig. 1). This result suggested there were other
interactions with the rGEP on the cell surface in
addition to HS. The current result corroborated a previ-
ous study that there were two types of binding sites for
GEP on epithelial and fibroblastic cells [22].
Identification of GRP78 as binding partner of GEP in
membrane fraction of HCC cells
Co-immunoprecipitation (co-IP) of the lysate of the mem-
brane fraction Hep3B-FLwith GEP antibody, compared
with the controls lysate alone and antibody alone respect-
ively, only one single extra band was observed in the co-IP
experiment. The SDS-PAGE gel was stained by Coomassie
blue and the protein band was excised for mass spec-
trometry analyzes. This unknown protein was identi-
fied as GRP78 according to the masses of the
trypsinized peptides in two independent runs (Table
1). Both independent runs identified the unknown
protein as GRP78 (P < 0.05). The details of the tryp-
sinized peptides were listed in Table 1.
Then, membrane fraction of another HCC cells,
HepG2-FL, was extracted for co-IP analysis to validate
the interaction between GEP and GRP78. As show in
the immunoblot of Fig. 2, using GEP antibody as bait
could co-immunoprecipitate GRP78, while GRP78 anti-
body could immunoprecipitate GEP.
Over-expression of GRP78 protein in HCC clinical samples
After identifying the GRP78 as a binding partner of GEP,
the protein expression of GRP78 was investigated in the
HCC clinical samples by immunohistochemistry (IHC).
Clinical samples that have shown over-expression of GEP
in our previous studies were further examined for GRP78
by IHC. Coincident to a previous finding in HCC [23], the
protein expression of GRP78 in HCC was shown to be
higher than the adjacent non-tumor liver tissue (Fig. 3).
Transcript expression of GRP78 correlates with GEP in
HCC clinical samples
The transcript level of GRP78 was determined by QPCR
from the cDNA reverse-transcripted from mRNA of
Fig. 4 Transcript levels of GRP78 and GEP in HCC samples. a GRP78 expression was up-regulated in HCC with reference to their corresponding
non-tumor (NT) (t-test, P = 0.002). (b-d) GRP78 and GEP transcript levels were significantly correlated when compared their HCC mRNA, NT mRNA
and the HCC versus NT fold ratio. e Kaplan-Meier analysis on recurrence-free survival. Patients were segregated based on their GRP78 mRNA levels
(log rank test, P = 0.022). The cut-off value of GRP78 expression level was determined by the Youden index
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patients’ HCC tumor tissues and non-tumor liver tissues.
From the 77 pairs of patient samples, statistical analyses
showed up-regulation of GRP78 in the HCC samples
when compared to the adjacent liver tissue (P = 0.002)
(Fig. 4a). Moreover, transcript expression levels of GEP
and GRP78 correlate significantly in HCC (Spearman’s ρ
correlation coefficient = 0.382, P = 0.001), non-tumor
(Spearman’s ρ correlation coefficient = 0.634, P < 0.001),
and the tumor-to-non-tumor fold change (Spearman’s ρ
correlation coefficient = 0.554, P < 0.001) (Fig. 4b-d).
GRP78 expression associates with HCC aggressive features
The mRNA expression levels of GRP78 from the HCC
tumor of 77 patients were divided into two groups with
high and low expression according to the cut-off defined
by receiver operating characteristic (ROC) curve ana-
lysis. Clinico-pathological features were analyzed against
the expression level of GRP78 (Table 2). Among them,
venous infiltration showed significant correlation with
high GRP78 expression. Coincidently, overexpression of
GRP78 in HCC has also been reported previously to
associate significantly with venous infiltration [24]. In
addition, the current study demonstrated that high level
of GRP78 expression correlated with poor recurrence-free
survival of the HCC patients (P = 0.022) (Fig. 4e). Venous
infiltration has been regarded as micro-metastasis and
may contribute to the poor recurrence-free survival
outcome of the HCC patients in GRP78 high expres-
sion group.
Thapsigargin and tunicamycin supports the translocation
of GRP78 to cell surface
Re-localization of GRP78 to the cell surface has been re-
ported previously. We tried to determine the re-localization
in GEP expression and cell surface binding of GEP. Thapsi-
gargin and tunicamycin, which induce ER stress by inhibit-
ing the fusion of autophagosomes with lysosomes and
inhibiting glycosylation, respectively, have been shown to
induce re-localization of GRP78 [25]. In both Hep3B and
HepG2 cell lines, incubation with indicated amount of
thapsigargin and tunicamycin for 16 h have led to the
increased overall and cell surface expression of
GRP78 (Fig. 5). However, both treatments have not in-
creased the overall and cell surface expression levels of
GEP (Fig. 5).
Discussion
In this study, we used co-IP and mass spectrometry to
identify GEP binding partner from the membrane-
enriched protein fraction of HCC cells. We have identified
GRP78 as a binding partner of GEP in Hep3B (Table 1)
Table 2 Clinico-pathological features of GRP78 expression in
HCC samples
GRP78
Clinico-pathological parameters Low High P valuea
Age
Young (≤60) 25 29 1.000
Elderly (>60) 11 12
Sex
Male 30 32 0.983
Female 6 9
Venous infiltration
Absent 23 14 0.044*
Present 13 27
Tumor stage
Early stages 23 28 0.997
Late stages 13 13
Tumor size
Small (≤5 cm) 9 9 0.999
Large (>5 cm) 27 32
aP value by chi-squared test with Bonferroni correction
Fig. 5 Biotinylation of cell surface proteins reflects the localization of
GRP78 and GEP under thapsigargin/tunicamycin treatments in (a)
Hep3B and (b) HepG2. Sortilin serves as positive control for cell
surface localization; while ERK1/2 and β-actin are negative controls.
1, before loading to avidin column; 2, flow through from the
column; 3, wash from the column; 4, elution of the biotinylated
cell surface proteins. Starting materials is 1.5 mg/ml. Loading volume
of 1 & 2 are 10 μl. Loading volume of 3 & 4 are 20 μl. Tg, 300 nM
thapsigargin; Tu, 1.5 μg/ml tunicamycin. Representative blots from
three independent experiments are shown
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and validated this interaction in another HCC cell line
HepG2 (Fig. 2). GRP78 has been shown to present
multifaceted subcellular positions and plays different
physiological roles in different subcellular locations. Most
GRP78 is retained in the ER, where it regulates unfolded
protein response (UPR) by releasing ER stress transducers,
PRKR-like ER kinase (PERK), inositol-requiring enzyme 1
(IRE1) and activating transcription factor 6 (ATF6), when
unfolded proteins accumulate [26]. GRP78 is redistributed
to mitochondria upon ER-stress, where it interacts with
Raf-1 to maintain the mitochondrial permeability and
inhibit ER-stress-induced apoptosis [27]. Accumulating
evidence demonstrated the re-localization of GRP78 to
plasma membrane, especially in the cancer cells that are
under stress [28]. Both ER stress and therapeutic resist-
ance promote the expression level and cell surface trans-
location of a subfraction of GRP78 [25, 29]. GRP78 on the
cell surface has been shown to regulate signaling pathways
[30–33]. Additionally, several molecules were shown to
support the surface re-localization of GRP78. Mtj-1 and
prostate apoptosis response 4 (PAR4) were shown to
transport GRP78 towards plasma membrane respectively
in murine tumor cells [34] and in prostate cancer cells
[35]. In the presence of activated form of alpha2-
macroglobulin (α2M), GRP78 was shown to translocate to
plasma membrane in HCC cells [33].
With respect to the nature of GRP78 relocalization
to cell surface, we attempted to determine if this re-
localization increased endogenous GEP expression or
on the cell surface of HCC cells; and if GRP78 con-
tributed to cell surface binding of rGEP. Consistent
with a previous study [25], higher level of cell surface
GRP78 was observed in HCC cells under the treat-
ment of thapsigargin and tunicamycin (Fig. 5). How-
ever, GRP78 re-localization did not affect the cell
surface levels of GEP (Fig. 5).
Clinical significance of GRP78 expression has been an-
alyzed. Coincident to a previous study of GRP78 at the
protein level [23], we demonstrated over-expression of
GRP78 in HCC tumor tissues compared to the non-
tumor counterparts at the transcript levels. Furthermore,
GRP78 over-expression was significantly associated with
venous infiltration (Table 2) and poor recurrence-free sur-
vival (Fig. 4), implying an important role of GRP78 in HCC
aggressiveness. Strikingly, expression levels of GEP are sig-
nificantly correlated with the expression levels of GRP78 in
both tumor and non-tumor tissues, indicating an associ-
ation between GEP and GRP78 expression in HCC.
The functional roles of GRP78 in HCC have been re-
vealed in previous studies. Over-expression of GRP78
and the consequential activation of UPR have been indi-
cated to confer drug resistance on HCC against sorafe-
nib and doxorubicin [36, 37]. GRP78 also plays a role in
invasion and metastasis of HCC cells through the
activation of FAK [38]. In the presence of the activated
form of alpha2-macroglobulin (α2M), GRP78 was shown
to translocate to plasma membrane and facilitate the
interaction between c-Src and EGFR, leading to invasion
and metastasis [33]. On the other hand, GEP has been
shown to co-express with ABCB5 and protect HCC cells
from chemotherapeutic agents including doxorubicin
[8]. The expression of GEP in HCC cells also contributes
to the invasiveness of HCC [7]. Therefore, the cell sur-
face and intracellular interaction between GEP and
GRP78 warrants further investigation to delineate their
roles in HCC tumorigenesis.
Conclusions
In summary, this study identified GRP78 from the mem-
brane fraction of HCC cells as a binding partner of GEP.
Their interaction may shed light on the multifaceted
roles of both GRP78 and GEP in HCC tumorigenesis,
especially their mechanistic relationship in cancer pro-
gression and drug resistance.
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